{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T03:24:30Z","timestamp":1771298670960,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2010,5,2]],"date-time":"2010-05-02T00:00:00Z","timestamp":1272758400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1007\/s00417-010-1397-7","type":"journal-article","created":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T13:29:30Z","timestamp":1272720570000},"page":"1757-1764","source":"Crossref","is-referenced-by-count":37,"title":["Comparison of the efficacy and tolerability of preservative-free and preservative-containing formulations of the dorzolamide\/timolol fixed combination (COSOPT\u2122) in patients with elevated intraocular pressure in a randomized clinical trial"],"prefix":"10.1007","volume":"248","author":[{"given":"Arthur","family":"Shedden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid A.","family":"Adamsons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert J.","family":"Getson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean K.","family":"Laurence","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher R.","family":"Lines","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Hewitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony W.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,5,2]]},"reference":[{"issue":"1","key":"1397_CR1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0039-6257(80)90072-7","volume":"25","author":"NL Burstein","year":"1980","unstructured":"Burstein NL (1980) Corneal cytoxicity of topically applied drugs, vehicles, and preservatives. Surv Ophthalmol 25(1):15\u201330","journal-title":"Surv Ophthalmol"},{"issue":"7","key":"1397_CR2","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/j.1755-3768.2008.01250.x","volume":"86","author":"C Baudouin","year":"2008","unstructured":"Baudouin C (2008) Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol 86(7):716\u2013726","journal-title":"Acta Ophthalmol"},{"issue":"3","key":"1397_CR3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/15569520902995834","volume":"28","author":"IP Kaur","year":"2009","unstructured":"Kaur IP, Lal S, Rana C, Kakkar S, Singh H (2009) Ocular preservatives: associated risks and newer options. Cutan Ocul Toxicol 28(3):93\u2013103","journal-title":"Cutan Ocul Toxicol."},{"issue":"11","key":"1397_CR4","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1001\/archopht.1994.01090230051020","volume":"112","author":"DC Broadway","year":"1994","unstructured":"Broadway DC, Grierson I, O\u2019Brien C, Hitchings RA (1994) Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch Ophthalmol 112(11):1437\u20131445","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"1397_CR5","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/IJG.0b013e31815c5f4f","volume":"17","author":"EW Leung","year":"2008","unstructured":"Leung EW, Medeiros FA, Weinreb RN (2008) Prevalence of ocular surface disease in glaucoma patients. J Glaucoma 17(5):350\u2013355","journal-title":"J Glaucoma."},{"issue":"7","key":"1397_CR6","first-page":"311","volume":"24","author":"R Zabel","year":"1989","unstructured":"Zabel R, Mintsioulis G, MacDonald I, Valberg J, Tuft S (1989) Corneal toxic changes after cataract extraction. Can J Ophthalmol 24(7):311\u2013316","journal-title":"Can J Ophthalmol"},{"key":"1397_CR7","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2165\/00002512-200017060-00005","volume":"17","author":"D Ormrod","year":"2000","unstructured":"Ormrod D, McClellan K (2000) Topical dorzolamide 2%\/timolol 0.5%: a review of its use in the treatment of open-angle glaucoma. Drugs Aging 17:477\u2013496","journal-title":"Drugs & Aging"},{"issue":"12","key":"1397_CR8","doi-asserted-by":"crossref","first-page":"977","DOI":"10.2165\/00002512-200623120-00005","volume":"23","author":"JE Frampton","year":"2006","unstructured":"Frampton JE, Perry CM (2006) Topical dorzolamide 2%\/timolol 0.5% ophthalmic solution: a review of its use in the treatment of glaucoma and ocular hypertension. Drugs Aging 23(12):977\u2013995","journal-title":"Drugs Aging."},{"key":"1397_CR9","unstructured":"Merck & Co., Inc. (2005) COSOPT\u00ae (dorzolamide hydrochloride-timolol maleate ophthalmic solution) sterile ophthalmic solution. Prescribing information. Available at: http:\/\/www.merck.com\/product\/usa\/pi_circulars\/"},{"issue":"10","key":"1397_CR10","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0161-6420(98)91046-6","volume":"105","author":"JE Boyle","year":"1998","unstructured":"Boyle JE, Ghosh K, Gieser DK, Adamsons IA (1998) A randomized trial comparing the dorzolamide\u2013timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide\u2013Timolol Study Group. Ophthalmology 105(10):1945\u20131951","journal-title":"Ophthalmology"},{"issue":"10","key":"1397_CR11","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1016\/S0161-6420(98)91047-8","volume":"105","author":"CM Clineschmidt","year":"1998","unstructured":"Clineschmidt CM, Williams RD, Snyder E, Adamsons IA (1998) A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide\u2013timolol combination to monotherapy with timolol or dorzolamide. Dorzolamide\u2013Timolol Combination Study Group. Ophthalmology 105(10):1952\u20131959","journal-title":"Ophthalmology"},{"issue":"11","key":"1397_CR12","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1136\/bjo.82.11.1249","volume":"82","author":"J Hutzelmann","year":"1998","unstructured":"Hutzelmann J, Owens S, Shedden A, Adamsons I, Vargas E (1998) Comparison of the safety and efficacy of the fixed combination of dorzolamide\/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. International Clinical Equivalence Study Group. Br J Ophthalmol 82(11):1249\u20131253","journal-title":"Br J Ophthalmol."},{"issue":"10","key":"1397_CR13","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/S0161-6420(98)91045-4","volume":"105","author":"K Strohmaier","year":"1998","unstructured":"Strohmaier K, Snyder E, DuBiner H, Adamsons I (1998) The efficacy and safety of the dorzolamide\u2013timolol combination versus the concomitant administration of its components. Dorzolamide\u2013Timolol Study Group. Ophthalmology 105(10):1936\u20131944","journal-title":"Ophthalmology"},{"issue":"1","key":"1397_CR14","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1046\/j.1600-0420.2004.0205.x","volume":"82","author":"RD Fechtner","year":"2004","unstructured":"Fechtner RD, Airaksinen PJ, Getson AJ, Lines CR, Adamsons IA, COSOPT versus XALATAN Study Groups (2004) Efficacy and tolerability of the dorzolamide 2%\/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials. Acta Ophthalmol Scand 82(1):42\u201348","journal-title":"Acta Ophthalmol Scand"},{"key":"1397_CR15","unstructured":"Merck, Sharp and Dohme Limited (2009) Cosopt preservative-free single dose eye drops. Summary of product characteristics. Available at: http:\/\/emc.medicines.org.uk\/medicine\/19142\/SPC\/Cosopt+Preservative-Free,+Single+Dose+Eye+Drops\/"},{"key":"1397_CR16","unstructured":"Merck Frosst (2009) COSOPT (dorzolamide hydrochloride and timolol maleate). Product monograph. Available at: http:\/\/www.merckfrosst.ca\/assets\/en\/pdf\/products\/COSOPT_0902-a_126262-E.pdf"},{"key":"1397_CR17","unstructured":"Laibovitz R, Zimmerman K, Getson A, Shedden A, Laurence J, Adamsons I (1999) Comparison of the efficacy and tolerability of preservative free 2.0% dorzolamide\/0.5% timolol (PF dorz\/tim) and 2.0% dorzolamide\/0.5% timolol (dorz\/tim). Invest Ophthal Vis Sci 40:S665 Abstract 3510\u2013B368"},{"issue":"9","key":"1397_CR18","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1023\/A:1015810619869","volume":"8","author":"P Ashton","year":"1991","unstructured":"Ashton P, Podder SK, Lee VH (1991) Formulation influence on conjunctival penetration of four beta blockers in the pigmented rabbit: a comparison with corneal penetration. Pharm Res 8(9):1166\u20131174","journal-title":"Pharm Res"},{"issue":"5","key":"1397_CR19","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/00003226-200107000-00013","volume":"20","author":"P Bijl Van der","year":"2001","unstructured":"Van der Bijl P, van Eyk AD, Meyer D (2001) Effects of three penetration enhancers on transcorneal permeation of cyclosporine. Cornea 20(5):505\u2013508","journal-title":"Cornea"},{"issue":"2","key":"1397_CR20","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000192082","volume":"41","author":"P Pellinen","year":"2009","unstructured":"Pellinen P, Lokkila J (2009) Corneal penetration into rabbit aqueous humor is comparable between preserved and preservative-free tafluprost. Ophthalmic Res 41(2):118\u2013122","journal-title":"Ophthalmic Res"},{"issue":"11","key":"1397_CR21","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s00417-008-0881-9","volume":"246","author":"C Erb","year":"2008","unstructured":"Erb C, Gast U, Schremmer D (2008) German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye. Graefes Arch Clin Exp Ophthalmol 246(11):1593\u20131601","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1397_CR22","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1136\/bjo.86.4.418","volume":"86","author":"PJ Pisella","year":"2002","unstructured":"Pisella PJ, Pouliquen P, Baudouin C (2002) Prevalence of ocular symptoms and signs with preserved and preservative-free glaucoma medications. Br J Ophthalmol 86:418\u2013423","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"1397_CR23","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/112067210701700311","volume":"17","author":"N Jaenen","year":"2007","unstructured":"Jaenen N, Baudouin C, Pouliquen P, Manni G, Figueiredo A, Zeyen T (2007) Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol 17(3):341\u2013349","journal-title":"Eur J Ophthalmol."}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-010-1397-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-010-1397-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-010-1397-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T19:40:56Z","timestamp":1559072456000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-010-1397-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,2]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["1397"],"URL":"https:\/\/doi.org\/10.1007\/s00417-010-1397-7","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,2]]}}}